Exclusive Summary

• Backed by US-FDA GMP certification and dual USP/EP compliant API, ensuring rapid registration and premium market access via reliance pathways globally.
• High technical barriers of complex liposomal injectables severely limit generic competition, providing distributors with robust differentiation and high-profit margins.
• Targets a massive global patient pool of over 2.6 million annually for breast/ovarian cancers, serving as a guideline-recommended WHO essential medicine with a superior safety profile.
• Leverages China's mature pharmaceutical supply chain and manufacturing capacity to offer significant cost and pricing advantages over originators and Western generics.